BNA's Web Watch - Antibiotic Use in Animals and its Impact on Human Resistance to Bacteria

(S. 549) Title: A bill to amend the Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases.
Summary
Status

(H.R. 962) Title: To amend the Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases.
Summary
Status

Government Accountability Office

FEDERAL OVERSIGHT OFFOOD SAFETY High-Risk Designation Can Bring Needed Attention to Fragmented System (February 8, 2007)

ANTIBIOTIC RESISTANCE Federal Agencies Need to Better Focus Efforts to Address Risk to Humans from Antibiotic Use in Animals (April 2004)

US Geological Survey
Are Pharmaceuticals in Your Watershed? Understanding the Fate of Pharmaceuticals and Other Contaminants in Watersheds

Food and Drug Administration
Guidance for Industry 152 - Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern, October 23, 2003
doc | pdf

Docket No. 1998D-1146, CVM 200381. Guidance for Industry: Evaluating the Safety of Antimicrobial New Animal Drugs With Regard to Their Microbiological Effects on Bacteria of Human Health Concern; Availability. Page 61221 [FR Doc. 03-27113] October 27, 2003

pdf

FDA Press Release - FDA Issues Guidance on Evaluating the Safety of Antimicrobial New Animal Drugs to Help Prevent Creating New Resistant Bacteria, October 23, 2003

GFI #152 Questions and Answers

Food and Drug Administration’s New Guidance For Industry on Antimicrobial Drugs for Food Animals, GFI #152, Released October 23, 2003 (PowerPoint Presentation)

Veterinary Medicine Advisory Committee (VMAC) Fall 2006 Meeting
Microbial food safety of an antimicrobial drug application currently under review for use in food producing animals in accordance with FDA/Center for Veterinary Medicine's Guidance for Industry #152
Meeting

Veterinary Medicine Advisory Committee (VMAC) Fall 2006 Meeting Presentations | Transcript
Cefquinome formulations for parenteral injection for the treatment of bovine respiratory disease Risk estimation under FDA/CVM Guidance #152 for cefquinome to evaluate potential microbiological effects on bacteria of human health concern (microbial safety)
(March 31, 2006)

National Antimicrobial Resistance Monitoring System http://www.fda.gov/cvm/narms_pg.html
National Antimicrobial Resistance Monitoring System (NARMS): Enteric Bacteria
http://www.cdc.gov/narms/

National Antimicrobial Resistance Monitoring System—Enteric Bacteria
(NARMS): 2003 Executive Report. Rockville, MD: U.S. Department of Health and Human Services, U.S. FDA, 2006.

The National Antimicrobial Resistance Monitoring System – Enteric Bacteria (NARMS) Retail Meat Annual Report for 2004 (September 21, 2006)

Centers for Disease Control and Prevention
A Public Health Action Plan to Combat Antimicrobial Resistance
2004 Annual Report

Antibiotic / Antimicrobial Resistance – Scientific and Other Publications

Nongovernment Organizations

Alliance for the Prudent Use of Antibiotics (APUA)
Global Advisory on Antibiotic Resistance Data (GAARD), entitled "Global Antimicrobial Resistance Alerts and Implications (March 2005)

Antibiotics in the ecosystem The Environmental Impact of Antibiotics ... A public awareness campaign

The Need To Improve Antimicrobial Use In Agriculture: Ecological And Human Health Consequences (Clinical Infectious Diseases)

American Veterinary Medical Association
Judicious Therapeutic Use of Antimicrobials (December 2005)

Animal Health Institute
Perspectives on the APUA FAAIR report

The Infectious Diseases Society of America
Bad Bugs No Drugs Advocacy Campaign: An Update
APUA Presentation, December 11, 2006 by Robert J. Guidos, JD, Director Public Policy & Government Relations

Bad Bugs, No Drugs As Antibiotic Discovery Stagnates . . . A Public Health Crisis Brews

Executive Summary

Clinical Infectious Diseases
Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America George H. Talbot,1 John Bradley,2,3 John E. Edwards, Jr.,4,5 David Gilber